Markets

FDA green lights Priovant drug for rare skin disease

1 source ·1 article ·1h ago

Lisraya’s clearance marks the first approval of a drug the Roivant subsidiary licensed from Pfizer and has since positioned against multiple rare inflammatory conditions.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·1h ago

FDA green lights Priovant drug for rare skin disease

Lisraya’s clearance marks the first approval of a drug the Roivant subsidiary licensed from Pfizer and has since positioned against multiple rare inflammatory conditions.

FDA green lights Priovant drug for rare skin disease

FDA green lights Priovant drug for rare skin disease →

FDA green lights Priovant drug for rare skin disease